In our weekly expert view piece, Dr Alan Marks, chairman of the Alliance for Patient Access, examines challenges faced by cancer patients in accessing precision medicine.
When former president Jimmy Carter announced at age 91 that breakthrough cancer drugs had eliminated his Stage IV melanoma, the hopes of patients and oncologists across the country soared.
Precision medicine is not just providing new treatment options; it is turning cancer care on its head. No longer do oncologists interpret certain diagnoses as near-certain death sentences.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze